- Home
- BE vs DYN Comparison
BE vs DYN Comparison
Compare BE & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BE
- DYN
- Stock Information
- Founded
- BE 2001
- DYN 1984
- Country
- BE United States
- DYN United States
- Employees
- BE N/A
- DYN N/A
- Industry
- BE Industrial Machinery/Components
- DYN Medicinal Chemicals and Botanical Products
- Sector
- BE Energy
- DYN Health Care
- Exchange
- BE Nasdaq
- DYN Nasdaq
- Market Cap
- BE 2.3B
- DYN 2.6B
- IPO Year
- BE 2018
- DYN 2020
- Fundamental
- Price
- BE $24.12
- DYN $23.99
- Analyst Decision
- BE Buy
- DYN Strong Buy
- Analyst Count
- BE 19
- DYN 11
- Target Price
- BE $23.00
- DYN $51.18
- AVG Volume (30 Days)
- BE 7.7M
- DYN 891.4K
- Earning Date
- BE 02-13-2025
- DYN 11-12-2024
- Dividend Yield
- BE N/A
- DYN N/A
- EPS Growth
- BE N/A
- DYN N/A
- EPS
- BE N/A
- DYN N/A
- Revenue
- BE $1,258,379,000.00
- DYN N/A
- Revenue This Year
- BE $9.34
- DYN N/A
- Revenue Next Year
- BE $19.20
- DYN N/A
- P/E Ratio
- BE N/A
- DYN N/A
- Revenue Growth
- BE N/A
- DYN N/A
- 52 Week Low
- BE $8.41
- DYN $12.06
- 52 Week High
- BE $28.70
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- BE 55.30
- DYN 32.86
- Support Level
- BE $21.91
- DYN $25.08
- Resistance Level
- BE $27.06
- DYN $26.69
- Average True Range (ATR)
- BE 2.03
- DYN 1.48
- MACD
- BE -0.79
- DYN -0.36
- Stochastic Oscillator
- BE 33.61
- DYN 5.29
About BE Bloom Energy Corporation
Bloom Energy designs, manufactures, sells, and installs solid-oxide fuel cell systems ("Energy Servers") for on-site power generation. Bloom Energy Servers are fuel-flexible and can use natural gas, biogas, and hydrogen to create 24/7 electricity for stationary applications. In 2021, the company announced plans to leverage its technology and enter the electrolyzer market. Bloom primarily sells its systems in the United States and South Korea.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.